CNGB was founded by the Chinese government and BGI to collect genomics technologies and resources, and promote their use by the research community.
The partners said they have agreed to work together on projects in a range of diseases, as well as establish research alliances with groups in China and Africa.
BGI was fined after found in 2015 to be conducting a genetics study illegally, according to the Global Times.
At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.
The companies will offer BGI's DNBseq next-generation sequencing technology along with Gencove's ImputeSeq low-pass sequencing analysis pipeline.
Researchers plan to sequence a hundred Pacific Northwest orcas to aid in their conservation, the Associated Press reports.
With NIPT samples from more than 141,000 women in China, investigators retraced population structure, historical migrations, genetic associations, and more.
The companies are developing a risk model to predict the likelihood that a prostate cancer patient will develop advanced or metastatic disease.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.